Genocea Biosciences, Inc. Announces Closing of $51.7 Million Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 818,181 shares of common stock, at the public offering price of $8.25 per share. The exercise of the underwriters’ option brought the total number of shares of common stock sold by Genocea to 6,272,726 shares and increased the total gross proceeds raised in this offering to $51.7 million, before deducting the underwriting discounts and commissions. The net proceeds to Genocea from this offering were approximately $48.4 million.

Cowen and Company and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Stifel is acting as lead manager and Needham & Company is acting as co-manager.

The offering was made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on March 2, 2015, and a related final prospectus supplement filed on March 12, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy and there shall not be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

The final prospectus supplement and accompanying prospectus is available for free by visiting EDGAR on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained from Cowen and Company c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by calling (631) 274-2806, or by fax (631) 254-7140 or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by calling (800) 747-3924, or by emailing [email protected].

About Genocea Biosciences, Inc.

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

Forward-Looking Statements

This press release includes forward-looking statements, including statements relating to the underwritten public offering. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea’s Annual Report on Form 10-K for the year ended December 31, 2014 and any subsequent SEC filings, including the registration statement and final prospectus supplement related to the offering. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements.

For media:
Spectrum Science Communications
Megan Lustig, O: 202-955-6222
[email protected]
or
For investors:
Genocea Biosciences, Inc.
Jonathan Poole, O: 617-715-7795
[email protected]

Source: Genocea Biosciences, Inc.

You May Also Be Interested In

• Biohaven Pharma (BHVN) Prices 5.6M Share Offering at $41/sh
• Trump Media & Technology Group (DJT) send letter to Nasdaq over “naked” short selling
• Bio-Path Holdings (BPTH) Announces 375K Share Offering at $3.225/sh